

TSLC-1 and STAT-3 Expression and Its Implication in Cervical Adenocarcinoma

Sadik Yusuf Musse^{1,2}

¹School of Medicine, Wuhan University, Wuhan, China

²Mmed in Urology Candidate: Urology Unit, Surgery Department, Kenyatta National Hospital, College of Health Sciences, University of Nairobi, Nairobi, Kenya

Email address:

Qabiile@students.uonbi.ac.ke

To cite this article:

Sadik Yusuf Musse. TSLC-1 and STAT-3 Expression and Its Implication in Cervical Adenocarcinoma. *Journal of Gynecology and Obstetrics*. Vol. 10, No. 2, 2022, pp. 108-119. doi: 10.11648/j.jgo.20221002.18

Received: March 16, 2021; **Accepted:** April 6, 2021; **Published:** March 23, 2022

Abstract: Inserting A549 the incorporation of cDNA into lung cancer (non-small cell) lines as well as tumor genomic clones repressor gene cancer of the lungs 1 (TSLC-1) helps these cell lines reverse tumor enlargement trends. Signal transducer and transcription activator 3 (STAT3) were phosphorylated chronically in 22 percent to 65 percent cancers of the non-small cell lung cancer. Tyrosine kinase receptors, for example EGFR (EGF stands for epidermal growth factor.), MET receptors as well as cytokine receptors, activate STAT3. IL-6, for example non-receptor kinases, as well as SRC were found to be involved as well. In resected NSCLC, overexpression of total or phosphorylated STAT-3 results in a poor prognosis. Gene expression and cell cycle variations show TSLC1 downstream pathways that serve as a bridge between the two repression of tumor products in A549 cells. The activation of STAT3 by stromal cells can be beneficial to NSCLC cell oncogenic outcomes.

Keywords: Endometrial Cancer, Tumor, Gene Expression, STAT-3, TSLC-1, NSCLC, Growth Factors, Pathways

1. Introduction

The substantial declines in both incidence and mortality rates of cervical cancers documented in the past 50 years is remarkable. With an estimated 493,000 new cases and 274,000 deaths in 2002, it is also the third most common cause of cancer in women worldwide [60]. Cervix is the tissue connecting the uterus and the vagina. It is divided into the upper or endocervix - lined with glandular cells - and the lower cervix or ectocervix - lined by stratified squamous epithelium. Cervical cancer starts in these lining cells, more commonly at the junction of these two cell types, also called as the transformation layer. Adenocarcinomas of the cervix develop in the endocervix from the glandular cells [70]. Glandular cells produce mucus in the endocervix. They account for almost 5-10% of vaginal cancer cases and the most common spread is hematogenous to lungs, and less commonly to the liver and bones. The Human Papilloma Virus (HPV), which is mostly spread through unprotected sexual contact, is the leading cause of cervical cancer, according to the CDC. Other than that, HIV, bearing more

than three children, multiple sexual

Cervical cancer rates have diminution significantly in both the incidence and the mortality over the final 50 years, that is impressive. The third leading cause of death in women worldwide is Cancer. In 2002, there were

There will be 493,000 new cases and 274,000 deaths, according to estimates [60]. The cervix is the tissue that connects the uterus to the vaginal canal. The upper cervix, The endocervix, also referred to as the cervix, is lined containing glandular cells, while the lower cervix, The ectocervix, also known as the cervix, is lined with stratified the squamous epithelium. Cervical cancer begins in these lining cells, most usually at the transition layer, which is the intersection of these two cell types. Cervical adenocarcinomas arise from glandular cells in the endocervix [70]. In the endocervix, glandular cells contain mucus. They account for nearly 5-10% of vaginal cancer cases, and the most common hematogenous spread is to the lungs, with less common spread to the liver and bones. According to the CDC, the Human Papilloma Virus (HPV), which is transmitted primarily by unprotected sexual encounters is the primary cervical cancer causes. HIV, having more than three children,

having multiple sexual partners, smoking, and using contraception for more than five years are all risk factors for cervical cancer (enter for disease control and prevention, 2019). Although gene mutation is inadequate to explain some biological changes in tumor development, more attention is being paid to epigenetic changes, which include DNA and RNA methylation, histone acetylation, ncRNA and chromatin control that is out of whack. Methylated modification has received a great deal of attention over the years. Methyl transferases within the DNMT family. TET proteins 5-methylcytosine can be oxidized (5-mC) in the formation of 5-hydroxymethylcytosine (5-hmC), 5-fC, and 5-caC, resulting in reversible methylation (DNMT family of methyltransferases mediates the conversion of the methyl group to cytosines, forming 5-methylcytosine (5-mC), which is oxidizable step by step by TET proteins into 5-hydroxymethylcytosine (5-hm [76, 80]. Methylation is used to decorate RNAs, RNAs, RNAs in the same way as it is used to decorate DNAs. M6A is a type of most methylation changes occur in nascent pre-mRNAs, according to a study of mRNA methylation markers [35]. Furthermore, miR-RNAs and lnc-RNAs participate in epigenetic changes, and methylation levels influence their biological functions. The link between HPV and abnormal DNA methylation in cervical cancer/CIN has been established.

Women who have a 2-fold rise in risk if a first-degree biological parent is affected are more likely to develop a cervical tumor than those who do not. 2016 (Galloway). Since HPV infections do not lead to malignant transformation an HPV-infected cell with a high risk of developing into an invasive carcinoma needs genetic changes as well [15]. According to the findings of a cell fusion study, HPV-infected cells must develop immortal and anchorage-independent phenotypes in order to be tumorigenic [52]. Cervical cancer has been diagnosed. linked to a variety of genetic mutations. TNF is involved in genes that are involved in cell growth death and apoptosis TNFa-8, TNFa-572, TNFa-857, TNFa-863, and TNF G-308A, among others, have been linked to an increased risk of cervical cancer. [1, 67, 23, 25]. When lung cancer tumor suppressor gene 1 (TSLC1) cDNA or genomic copies are inserted A549 non-small cell lung cancer cell line, the cells' tumor characteristics of growth are reversed. These findings, along with the fact that TSLC-1 expression is reduced in a variety of tumors, indicate that it is a crucial switch that inhibits tumorigenesis [54]. The TSLC1 protein is downregulated in NSCLC and a number of other cancers. Pancreatic cancer is one of them. Hepatocellular carcinoma [45] breast carcinoma [2], prostate carcinoma [49], nasopharyngeal carcinoma [31], gastrointestinal carcinoma [53], and cervical carcinoma.

2. Literature Review

TSLC-1 in adenocarcinomas

To help cell adhesion, TSLC-1 generates a transmembrane glycoprotein that forms dimers both within and between cells [49]. Immunoglobulin superfamily members, NCAM

adhesion proteins, and Ca²⁺-independent cell-cell adhesion proteins from the nectin family all share structural domains with this protein [39, 64]. It is made up of interactions between two protein domain names that are essential in order to suppress tumor growth function. SgIGSF, RA175, NECL2 IGSF4, BL2, ST17 and SynCAM1, are all names given to the TSLC1 gene, which has occurred isolated in a variety of laboratory paradigms [64, 24, 72].

Since TSLC1 can reverse the A549 cell is a very violent cell. line's tumorigenic and metastatic properties on its own, it is important to identify the active tumor suppressor's downstream effectors. The identification of active TSLC1 genes or pathways will help researchers better understand the molecular switch from tumorigenic to no tumorigenic development. The effects of restoring TSLC1 expression to normal levels on growth were studied, and the underlying gene expression changes were classified using a variety of techniques.

Many genes involved in Ras-induced senescence, endometrial stromal cell differentiation, and trophoblast implantation in the uterus were identified found to be governed selectively. The manifestation of additional genes involved in cell division formation, adhesion, and energy production was altered. None of the previously described cell cycle regulatory pathways appear to be used by TSLC1. In small amounts of tumor and normal tissue from histological specimens, certain variations in expression were confirmed. This tumor suppressor's analysis in the easily accessible A549/12.2 cell system will also provide insights into a new gene expression cascade involved in transformation. repression. We may draw similar conclusions about cervical adenocarcinoma from a study that looked at the impact of TSLC-1 on lung cancer. The research looks at how TSLC-1 affects A549 cells, which are adenocarcinomic basal epithelial cells that are usually found in the lungs. Since TSLC-1 is expressed and controlled in NSCLC and other neoplasias, this research will aid in the understanding of gene pathogenesis in cervical adenocarcinoma by comparing it to similar mechanisms seen in lung adenocarcinomas. According to Sussan et al., To identify genes that were differentially expressed when TSLC1 levels were restored to normal., subtractive hybridization was used to compare A549 cells to suppressed 12.2 cells. The method was used to generate two distinct populations of enriched cDNA for up-regulated messages in A549 or 12.2, respectively. Both cDNA populations were hybridized to Genome Systems' cDNA arrays, revealing 41 genes significantly over-expressed in the tumorigenic A549 line and 18 genes significantly over-expressed in the suppressed 12.2 cell line (Table 1). Among other things, the differentially expressed genes were found to be involved in cell proliferation, cell survival, protein phosphorylation, immune response, cell adhesion, and detoxification, among other functions. Differential expression was also found in some genes whose products are found in mitochondria.

Table 1. The Expression of Genes in 12.1 Cell Lines and A549.

Gene	Up-Regulated	Assay	Fold Expression Difference	Functional Class
Fibrinogen beta chain (<i>FGB</i>)	A549	SH/qPCR	2737.5+/-1058.5	Adhesion
Fibrinogen gamma chain (<i>FGG</i>)	A549	SH	ND	Adhesion
Adenomatous polyposis coli (<i>APC</i>)*	A549	qPCR	1.7+/-0.2	Cellular Growth
Cyclin D1 (<i>CCND1</i>) [†]	A549	qPCR	1.6+/-0.0	Cellular Growth
β-catenin 1 (<i>CTNNB1</i>)*	12.2	qPCR	1.1+/-0.0	Cellular Growth
Dishevelled 1 (<i>DVL1</i>)*	A549	qPCR	1.1+/-0.3	Cellular Growth
v-Ha-ras Harvey rat sarcoma viral oncogene homolog (<i>HRAS</i>) [†]	A549	qPCR	1.4+/-0.3	Cellular Growth
Lymphoid enhancer-binding factor 1 (<i>LEF1</i>)*	12.2	qPCR	3.4+/-0.4	Cellular Growth
v-myc myelocytomatosis viral oncogene homolog (<i>MYC</i>) [†]	A549	qPCR	1.3+/-0.2	Cellular Growth
Interleukin 23-alpha (<i>IL23A</i>) [†]	A549	qPCR	1.0+/-0.0	Cellular Growth
Tumor protein p53 (<i>TP53</i>) [†]	A549	qPCR	1.7+/-0.3	Cellular Growth
Retinoblastoma 1 (<i>RB1</i>) [†]	12.2	qPCR	1.3+/-0.4	Cellular Growth
S100 calcium-binding protein P (<i>S100P</i>)	A549	SH/qPCR	1680.0+/-955.4	Cellular Growth
Transcription factor 4 (<i>TCF4</i>)*	12.2	qPCR	6.8+/-2.0	Cellular Growth
Transcription factor 7-like 2 (<i>TCF7L2</i>)*	12.2	qPCR	2.2+/-0.7	Cellular Growth
Transmembrane 4 superfamily member (<i>TM4SF4</i>)	A549	SH/qPCR	475.2+/-328.0	Cellular Growth
Centromere protein E (<i>CENPE</i>)	A549	SH	ND	Cellular Growth
Heat shock protein 70B (<i>HSPA6</i>)	A549	SH/qPCR	2.4+/-0.8	Chaperone
Insulin-like growth factor binding protein 1 (<i>IGFBP1</i>)	A549	SH/qPCR	15.9+/-7.4	Decidualization [41]
Retinoid X receptor RXR (DR-1)	A549	TS	2.7	Decidualization [42]
Aldehyde dehydrogenase 1 (<i>ALDH1</i>)	A549	SH/qPCR	4.2+/-0.1	Decidualization-Implantation [43]
Annexin A2 (Lipocortin II) (<i>ANXA2</i>)	12.2	SH/qPCR	3.1+/-1.0	Decidualization-Implantation [43]
Metallothionein-IF (<i>MTIF</i>)	12.2	SH	ND	Decidualization-Implantation [43]
Metallothionein-IG (<i>MTIG</i>)	12.2	SH/qPCR	37.1+/-10.4	Decidualization-Implantation [43]
Cadherin 11 (OB-cadherin, osteoblast) (<i>CDH11</i>)	A549	SH/qPCR	5.6+/-2.7	Decidualization-Luteal/Adhesion [34, 44]
Fibroblast growth factor 9 (<i>FGF9</i>)	A549	SH	ND	Decidualization-Proliferation [45]
Promyelocytic leukemia gene (<i>PML</i>)	A549	SH	ND	Decidualization-Proliferation
Similar to aldehyde dehydrogenase 6 (<i>ALDH1A3</i>)	A549	SH	ND	Dehydrogenase
3-alpha hydroxysteroid dehydrogenase type II (<i>AKR1C3</i>)	A549	SH	ND	Dehydrogenase
Dihydrodiol dehydrogenase 2 (<i>AKR1C2</i>)	A549	SH/qPCR	22.9+/-2.4	Dehydrogenase
Kinesin 2, light chain (<i>KNS2</i>)	12.2	SH/qPCR	3.9+/-0.0	Intracellular Trafficking
Matrix metalloproteinase 1 (<i>MMP1</i>)	12.2	qPCR	1.2+/-0.4	Invasion
Vascular endothelial growth factor (<i>VEGF</i>)	12.2	qPCR	4.2+/-0.3	Invasion
Ferritin, heavy chain (<i>FTH1</i>)	12.2	SH/qPCR	2.7+/-1.7	Iron Binding
Metallothionein-IE (<i>MTIE</i>)	12.2	SH/qPCR	14.8+/-8.5	Metal Homeostasis
Metallothionein-IH (<i>MTIH</i>)	12.2	SH	ND	Metal Homeostasis
Metallothionein-IL (<i>MTIL</i>)	12.2	SH/qPCR	5.8+/-0.9	Metal Homeostasis
Metallothionein-IR (<i>MTIR</i>)	12.2	SH	ND	Metal Homeostasis
Manganese-containing superoxide dismutase (<i>SOD2</i>)	A549	SH/qPCR	2.0+/-0.6	Mitochondrial
Microsomal glutathione transferase (<i>MGST1</i>)	A549	SH/qPCR	2.3+/-0.1	Mitochondrial
NAD(P)H menadione oxidoreductase 1, dioxin-inducible (<i>NQO1</i>)	A549	SH/qPCR	3.1+/-0.1	Mitochondrial
Solute carrier family 25 member 5 (<i>SLC25A5</i>)	A549	SH/qPCR	3.4+/-0.3	Mitochondrial
Myelin proteolipid protein (<i>PLP</i>)	A549	SH	ND	Myelin Constituent
Ribosomal protein S6 (<i>RPS6</i>)	12.2	SH/qPCR	2.5+/-1.2	Protein Kinase
v-ets erythroblastosis virus E26 oncogene homolog 2 (<i>ETS2</i>)	A549	qPCR	1.2+/-0.0	Ras-Induced Senescence [29]
Metallothionein-II (<i>MTII</i>)	12.2	SH	ND	Ras-Induced Senescence [29]
Ras induced senescence 1 (<i>RIS1</i>)	12.2	SH/qPCR	80.2+/-62.3	Ras-Induced Senescence [29]
Tissue inhibitor of metalloproteinase 1 (<i>TIMP1</i>)	12.2	qPCR	2.2+/-0.1	Ras-Induced Senescence [29]
CAAT box general (CBF)	12.2	TS	2.5	Transcription Factor
CCAAT displacement protein (CDP)	12.2	TS	2	Transcription Factor
E2F transcription factor 1 (E2F-1)	12.2	TS	2.4	Transcription Factor
Early growth response (EGR)	12.2	TS	3.4	Transcription Factor
Estrogen receptor (ERE)	12.2	TS	2.5	Transcription Factor
GATA binding protein (GATA)	12.2	TS	2.1	Transcription Factor
Glucocorticoid receptor (GRE)	12.2	TS	3	Transcription Factor
Nuclear factor of activated T-cells, cytoplasmic (NF-ATc)	12.2	TS	3.1	Transcription Factor
Signal transducer and activator of transcription 3 (STAT3)	A549	TS	2	Transcription Factor
Signal transducer and activator of transcription 4 (STAT4)	A549	TS	2.3	Transcription Factor
Upstream transcription factor (USF-1)	A549	TS	2.5	Transcription Factor
Transcription co-activator Sp110	A549	SH	ND	Transcription Factor

Gene	Up-Regulated	Assay	Fold Expression Difference	Functional Class
Similar to eukaryotic translation initiation factor 2B, subunit 1 (EIF2B1)	A549	SH	ND	Translation
Insulin-like 4 (<i>INSL4</i>)	A549	SH/qPCR	27.0+/-15.8	Trophoblast [46]
Keratin 8 (<i>KRT8</i>)	A549	SH	ND	Trophoblast [47]
cDNA clone DKFZp761C1 (AL157447)	A549	SH	ND	Unknown
cDNA clone FLJ20643 (AK000650)	A549	SH	ND	Unknown
FLJ14639 (NM_032815)	A549	SH	ND	Unknown
Hit clone 451B21 (AL033522)	A549	SH	ND	Unknown
HSA1p34 genomic sequence (AL009181)	A549	SH	ND	Unknown
Rhomboid family 1 (Z69719) (<i>RHBDF1</i>)	A549	SH	ND	Unknown
RP11-2H8 (AC089984)	A549	SH	ND	Unknown
RP11-389E6 (AL359836)	A549	SH	ND	Unknown
RP11-478J18 (AC011700)	A549	SH	ND	Unknown
RP11-7F24 (AC018841)	A549	SH	ND	Unknown
RP1-20C7 (AL136304)	A549	SH	ND	Unknown
SR+89 (Z69706)	A549	SH	ND	Unknown
HSA14 genomic sequence (AL135745)	12.2	SH	ND	Unknown

1. * Wnt/ β -catenin pathway

2. [†]G1/S transition

(Sussan et al., 2005)

2.1. Table 1 & 2 Analysis

The expression of genes was compared in the 12.2 cell lines and A549. To recognize genes that were pronounced differently in 12.2 cells, qPCR A549, qPCR subtractive hybridization (SH), and/or a combination of the two Trans Signal DNA-protein array (TS) were used for each, relative quantification differences were estimated. genes evaluated by TS; ND or qPCR was not calculated.

TSLC-1's cell growth altering mechanism

qPCR was used to compare transcript levels for 31 of the differentially expressed genes (Table 1). Normalized expression alpha-tubulin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (TUBA1). QPCR revealed that TSLC1 expression was 2.8+/-0.8 times higher in 12.2 than in A549. Twenty-one of the 31 qPCR genes investigated displayed two fold or greater expression differences in the subtractive hybridization-predicted direction Contrary to subtractive hybridization, one gene, complement component C5 (CCC5), was down-regulated 13.8+/-4.7-fold in 12.2 cells

findings. As well as nine genes are remaining have been altered by less than a factor of two. Some genes involved in cellular proliferation were found to be overexpressed in A549 but not in 12.22. (Table 1).

12.2 also reduced the expression of Cadherin 11 (CDH11), a protein involved in cell-cell interactions. Furthermore, in 12.2, some mitochondrial genes were downregulated. (See Table 1). RIS1 (Ras-induced senescence 1), metallothionein 1G (MT1G), and metallothionein 1EE (MT1EE) were the most significantly upregulated genes in 12.2 cells (MT1EThe expression of genes in normal circumstances versus tissues of tumor was compared to determine whether variations reflect in 12.2 and A549 cells in vivo alterations (Table 2). Tissues were extracted transcript levels were determined using pathological specimens determined using qPCR stands for quantitative polymerase chain reaction., which was GAPDH-normalized (Fukami et al.). In 5/5 tumors, SLC1 and RIS1 levels were lower than expected average, S100 calcium binding protein P (S100P) and IGFBP1 (insulin-like growth factor binding protein 1) levels were higher.

Table 2. Relative Gene Expressions in Tumors.

	Relative Gene Expression in Tumors			
	<i>TSLC1</i>	<i>RIS1</i>	<i>S100P</i>	<i>IGFBP1</i>
Patient 1	-25.7	-2.3	33.3	600
Patient 2	-23.8	-6.4	2.1	2.3
Patient 3	-16.9	-7.1	28.1	-8.4
Patient 4	-344.3	-43.9	3.2	6.1
Patient 5	-32.4	-44.9	16.1	1.9
Cell Lines	Down in A549	Down in A549	Up in A549	Up in A549

(Sussan et al., 2005)

Sussan, T. E., Pletcher, M. T., Murakami, Y. and Reeves, R. H. (2005). Tumor suppressor in lung cancer 1 (TSLC1) alters tumorigenic growth properties and gene expression. *Molecular Cancer*, 4 (1), p. 28.

As a result, major variations in Cell lines that have been transformed (A549) and suppressed (12.2) indicate physiological distinctions observed when comparing tumor to normal tissue [69].

The profiles of gene expression of NSCLC is an abbreviation for Non-S tumors and lung health tissue are equivalent to those of A549 and 12.2. qPCR was used to assess relative fold expression differences in cancers and

compare them from normal lung tissue the same patient. Positive characteristics indicate increased articulation in the tumor, while negative numbers indicate increased articulation in normal tissue.

2.2. Expression of Signaling Pathway Genes

Because of we used quantitative RT-PCR to look at the expression of many recognized genes for checkpoints and signaling to see whether there were any variations between A549 and 12.2 in terms of cell cycle profiles and growth rates pathways (qPCR). In some NSCLCCs, changes in the Ras/p53 signaling pathway cause an irregular S/G1 switch (Lazo, 1999). The mRNA levels of HRAS, TP53, p19 and RB1, on the other hand, did not differ significantly between the numbers A549 and 12.22. (Please see Table 1). The insignificant variations were no differences in expression levels. organized in a manner clarified the G1/S transition lengthening in 12.2 cells MYC and cyclin D1 are both transcription factors (CCND1), two proteins that help in the transition from G1 to S, were also studied. There has been no improvement in the expression of CCND1 or MYC, its upstream regulator. As a result, none one of these well-established paths appears to be caused by the G1 postponement.

TSLC-1 expression results

This is in contrast to line 12.2, which has a healthy TSLC1 expression has been restored but no improvement in the staining with in the staining with annexin V. Since the 12.2 cell line was selected after TSLC1 transfection, it provides information about TSLC1's normal function in non-transformed cells. When compared to transformed lung tissue, TSLC1 has the ability to suppress A549's transformed growth properties and alter the profile of A549's gene expression to resemble normal. Its normal function as a powerful tumor suppressor can include controlling cell growth by inducing apoptosis in some rare cancer cells. These differences in growth-related properties between A549 and 12.2 were identical to those observed previously when tumor cells were transfected with a TSLC1 cDNA or genomic clone-containing vector [39, 54, 33]. To establish which gene groups were affected by TSLC1 expression restoration in 12.2, researchers examined gene expression associated with A549 and 12.2 adhesion, invasion, basal metabolism, cell formation, senescence, and apoptosis. The putative tumor suppressor Ras-induced senescence 1 was the most up-regulated gene in 12.2 cells (RIS1). RIS1 is found on 3p21.3, a region of the genome that is often deleted in human tumors [36]. RIS1 is located in a 1 Mb human chromosomal region that is normally deleted in human/mouse microcell hybrids passing through SCID mice during tumor formation [79]. The presence of one or more unidentified tumor suppressors in this area of chromosome 3 known as typical removed region 1 has been confirmed (CER1). These findings are encouraging for RIS1 as a potential candidate. In 12.2 cells, we found elevated levels of RIS1, multiple metallothioneins, and TIMP1, which is consistent with the results of this study. The regulation of these genes suggests that the Ras-induced

senescence pathway is linked to TSLC1-mediated tumorigenesis inhibition. RIS1 expression in human fibroblast IMR90 cells has previously been related to ETS2, a Ras-induced senescence inducer [6]. ETS2 expression did not vary between A549 and 12.2 cells in this study (Table 1), indicating that RIS1 activation in 12.2 cells was mediated by a different mechanism.

Some of the differentially expressed genes in this sample have previously been shown in non-overlapping studies to be differentially expressed during various stages of endometrial stromal cell decidualization and trophoblast implantation (Table 1). These processes have no direct connection to neoplastic transformation in NSCLC. It's intriguing that these seemingly unrelated events have the same gene expression patterns. Decidualization and implantation differentiate transformed cells that have elevated levels of proliferation and tissue invasion. These findings suggest that TSLC1 can suppress transformed development through some of the same pathways that regulate endometrial cell proliferation at various stages of decidualization VEGF expression was elevated in 12.2 percent of the patients cells matches results from other tissues, suggesting that this gene is upregulated in tumor cells. As a result, TSLC1 has no effect on tumorigenesis through any of the conventional pathways. However, some of these genes are regulated by protein or nucleoplasm regionalization.

Acute expression of TSLC-1

It's crucial to understand how acute TSLC1 expression in A549 cells affects In 12.2 cells, cell cycle profiles differed from long-term restoration of this gene. 3 to 5 days of infection with TSLC1 cDNA (Ad-TSLC1) expressing adenovirus vectors, infected cultures showed apoptosis and increased annexin V staining [48]. This is in contrast to line 12.2, which has a healthy TSLC1 expression has been restored but no improvement with in staining with annexin V Since the 12.2 cell line was selected after TSLC1 transfection, it provides information about TSLC1's normal function in non-transformed cells. When compared to transformed lung tissue, TSLC1 has the ability to suppress A549's transformed growth properties and change the profile of A549's gene expression to resemble normal. Its normal role as a powerful tumor suppressor may include regulating cell development by inducing apoptosis is a type of cell death some rare cancer cells.

An introduction to STAT-3

The transducer of signals and transcription 3rd activator (STAT3), a central signaling intermediary in cancer, is persistently activated in 22 percent to 65 percent of patients. [84, 44, 82]. The activation of STAT3 by cytokines such as interleukin-6 (IL-6) is regulated by Janus family kinases (JAK) or SRC kinases (Src-6) [42]. STAT3 is also involved in the function of one of the e real growth factor receptors (EGFR) downsneam channels [83]. In vitro and in vivo trials, some JAK/STAT3 inhibitors inhibited STAT3 activation and had anticancer and antiangiogenic properties. Some have been enrolled in solid tumor clinical trials [41, 73, 53]). STAT3's role in malignant diseases the topic of cancer,

especially NSCLC, will now be addressed. In EGFR-mutated NSCLC, the STATE pathways are also studied. Despite the fact that STATs have a wide range of immunoregulatory features, they have been thoroughly studied investigated or summarized [56, 57]. In this review, oncogenic effects of STAT3 were also investigated.

The characteristics of STAT transcription factors

Malignant carcinogenesis developments, formation of tumor, as well as metastatic disease all possess signal pathways routes that have been found Oncogenic signaling has also been studied in RAS/MAPK and PI3K/AKT pathways [12, 18, 74, 28]. STAT, a cytoplasmic protein containing Src homology 2 (SH2) domains is among the most recent Pathways of oncogenic signaling to be identified. In normal cells, they serve as transcription factors, responding in relation to cytokines and growth factors. This protein family consists of seven members. STAT1-4, STAT6, as well as STAT5a and STAT5b proteins, are all related. STATs are activated by phosphorylation of a conserved tyrosine residue. After dimerization, they translocate to the nucleus, bind to DNA, and activate the target genes [7, 16]. IL-6, IL-2, IL-7, Epidermal growth factor (EGF), fibroblast growth factor, and platelet-derived growth factor are cytokines and growth factors that phosphorylate the tyrosine residue. JAK and Src tyrosine kinases, for example, are activated immediately after growth factors or cytokines bind to their respective receptors [8, 81]. Tyrosine kinases phosphorylate the receptor, allowing monomeric STATs to bind to it and provide docking sites. After activation, STATs become tyrosine phosphorylation substrates. Regardless of receptor activation, non-receptor tyrosine kinases such as Src and Bcr-Abl can phosphorylate STATs. Phosphorylated (p) STATs dimerize and transfer to the nucleus, where they regulate gene expression [81]. The COOH termini of STAT1, STAT3, and STAT5 are all phosphorylated on a serine residue; this phosphorylation is not needed for dimerization, nuclear translocation, or DNA binding, but it is required for certain genes to have optimal transcriptional operation [17]. These proteins serve as cytoplasmic signaling proteins and nuclear transcription factors that activate a diverse set of cancer-related genes. The activation of STATs target genes, which also regulate the cell cycle, promotes cell growth and results in a cancerous phenotype. STAT-3 is linked to oncogenesis and chemotherapy resistance, according to research.

Expression of STAT-3 and its implications on tumor cell growth

Despite the fact that STAT signaling is activated is tightly regulated in healthy cells and is required for a variety of Cell growth and differentiation, metabolism, hematopoiesis, and host defense are all examples of biological processes and immunoregulation are all examples of cell functions., it is constitutive in malignant tumors because of the permanent tyrosine kinase activation, especially STAT3 and STAT5. [81, 57, 10, 57, 81, 57]. The embodiment of genes that govern cancer progression pathways, such as unregulated

proliferation, resistance to apoptosis, prolonged angiogenesis, and immune surveillance avoidance, increases after STATs activation will alter [81, 10, 11, 29]. Recent Evidence suggests that STAT family proteins, particularly STAT3, play a role in the establishment and maintenance of a pro-carcinogenic inflammatory microenvironment at the onset of malignant transformation and during cancer progression. [47, 38, 75, 75, 27, 62, 4, 63]. In several studies, STAT3 Inhibition has been shown in a number of cancer types to suppress cancer cell growth and improve anticancer drug resistance. STAT3 has also been suggested as a cancer therapeutic goal.

STAT-3 effect on prognosis in NSCLC

Several studies investigated the clinical importance of STAT3 or pSTAT3 expression in patients, as well as the relationship between STAT3 expression or pSTAT3 in addition NSCLC forecast [82, 77]. There were 127 cases of p-STAT3 immunoreactivity among the 127 cases. in patients with lymph node metastasis (78.8 percent (41/52)), immunohistochemically staining was found to be significantly linked to sex ($p = 0.004$) and history of smoking ($p = 0.006$). This was significantly higher than the 54.7 percent (41/75) of Patients with non-lymph node metastasis of NSCLC [82]. In a meta-analysis involving 17 retrospective trials, Xu and colleagues discovered that high STAT3 or pSTAT3 expression in NSCLC patients is a strong predictor of poor prognosis [77]. Zhao and colleagues. Patients with NSCLC who have high pJAK2 expression have a significantly lower overall survival rate after surgery than patients with low pJAK2 expression [82]. They also discovered that NSCLC samples expressing elevated levels of pJAK2 and pSTAT3 had higher micro vessel density (MVD), and that patients with severe MVD have a lower chance of survival. High pSTAT3 expression in NSCLC patients is a good indicator of poor prognosis, according to these findings it needs to, however be checked in a broad longitudinal long-term follow-up analysis.

STAT-3 Expression Downstream EGFR Pathways

There are numerous pro-inflammatory cytokines and growth factors present, all of which activate EGFR STAT3 on their own. Some tumor cell lines require constant STAT3 activation in order to survive [10, 19, 13, 45, 51], as well as hepatocyte growth factor (HGF) and its receptor (c-MET) in cells of leiomyosarcoma and breast cancer adenocarcinomas of the female reproductive system [13, 45, 32, 55]. STAT3 is an oncogene found in alveolar type II epithelial cells of NSCLC [11, 78].

Chronic activation of STAT3 in transgenic STAT3 mice resulted in pulmonary tumorigenesis, according to Li et al [43]. The activation of STAT3 by receptor tyrosine kinases like EGFR and MET, as well as cytokine receptors like IL-6 receptors and non-receptor kinases like Src, regulates the survival mechanism in certain NSCLC cells [65]. According to Zimmer et al., STAT3 activity contributes to the carcinogenic potential of NSCLC regardless of EGFR mutations [84].




Figure 1. STAT-3 converging on signaling pathways.

Figure 1 Receptor Tyrosine kinases of the Janus family (JAKs) are activated by this. cross-phosphorylation following JAKs activation and cytokine-receptor binding Then, inside receptor molecules, phosphorylate tyrosine residues., resulting in cytoplasmic STAT docking components STATs form dimers after being on a single tyrosine residue phosphorylated when one STAT molecule's phosphotyrosine interacts with another's Domain of Src homology-2 (SH2) dimers shift towards the nucleus and bind to unique regulatory elements that promote the transcription of the target gene. Intrinsic tyrosine kinase activity (RTK) STATs can be triggered directly by means of receptors without the need as well as JAK activation. The platelet-derived growth factor receptor (PDGFR) and the epidermal growth factor receptor (EGFR) are two types of growth factor receptors. two examples (EGFR). STATs like Bcr-Abl and Src non-receptor protein tyrosine kinases that are constitutively active will phosphorylate it (PTKs). PIAS stands for activated STAT protein inhibitor; PTK stands for IL-6; protein tyrosine kinase stands for interleukin-6, P stands for phosphorus, SOCS stands for cytokine signaling suppressor. [22]

STAT3 has also been identified discovered as an example a middleman EGFR mutation-induced effects oncogenic [3]. In several NSCLC cell lines, STAT3 is active all of the time [65]. Non-transformed epithelial cells designed to produce different mutations in the EGFR related with NSCLC had more significant levels of STAT5 and STAT3 [66]. According to Greulich et al., STAT3 has caused many EGFR changes, remembering exon 19 for outline cancellation or exon 21 L858R point transformation, which can cause oncogenic effects in human lung cancer fibroblasts and cells [26]. STAT3 is activated indirectly by mutant EGFR because the

cytokine IL-6 needs upregulation.

3. Methods

This was qualitative research, and it was conducted through extensive research present in digital libraries. This was qualitative research, and it was conducted through extensive research present in digital libraries. In February 2021, an independent viewer performed a thorough literature review using directories such as PubMed, NIH, Hindawi, Oncomed, Chinese Biomedical Literature Database, and others. Clinical trials were the only ones that were found during the search after for each term, In the title and abstract, conduct a text word search was combined with topic heading searches. The search was limited to endometrial cancer and the tumor lines involved in causing proliferation of cancer. The STAT-3 and TSCL-1 genes were search for individually, and complicity to select relevant articles. The evaluator also conceptually inspected the findings to sequentially eliminate any noticeable unimportant publications, as well as inspecting the Medline database of the selected studies to find further relevant articles.

4. Conclusions

The A549 tumor cell line lost transformed growth properties after TSCL1 levels were restored, consisting of a lower cell replication a slower pace of development through the cell cycle from G1 to S. This was accompanied by endometrial decidualization and a shift in profile of gene expression, with improvements in genes associated with Ras-induced senescence functions.

Several genes involved in cell division, including IGFBP1, S100P in addition INSL4. When TSLC1 levels were restored, the results were different. TSLC1 appears to work independently of each of the various well-studied cell growth regulatory pathways both the lung and the many other tissues in which TSLC1 has happened linked to development of cancer, will have a major effect on cancer biology to describe the mechanisms by which TSLC1 inhibits tumorigenesis. This research uncovers a slew of cellular phenotypes linked to TSLC1 expression and sheds light on TSLC1-induced genes and molecular pathways. The STAT3 signaling pathway is involved. in conjunction with in number because of cancer, as well as NSCLC. JAK/STAT3 inhibitors can be used to treat NSCLC regardless of whether the patient has an EGFR mutation. The mechanism (s) by which paracrine, autocrine, or ligand sources from the stroma activate STAT3 must be elucidated. The activation of STAT3 by stromal cells will cause NSCLC cells to become oncogenic. STAT3's function in therapeutic resistance should be investigated. Then be determined. Finally we have the most promising ways to employ JAK or STAT inhibitors in a clinical setting must be investigated such as well as whether they function as a stand-alone treatment or just as part of a mix. To better understand the potential roles in the treatment of NSCLC of STAT3 inhibitors, further translational and clinical trials are needed.

References

- [1] Abrahamsson, J., Carlsson, B. and Mellander, L. (1993). Tumor necrosis factor- α in malignant disease. *The American Journal of Pediatric Hematology/Oncology*, [online] 15 (4), pp. 364–369. Available at: <https://pubmed.ncbi.nlm.nih.gov/8214357/> [Accessed 25 Feb. 2021].
- [2] Allinen, M., Peri, L., Kujala, S., Lahti-Domenici, J., Outila, K., Karpunen, S.-M., Launonen, V. and Winqvist, R. (2002). Analysis of 11q21-24 loss of heterozygosity candidate target genes in breast cancer: Indications of TSLC1 promoter hypermethylation. *Genes, Chromosomes and Cancer*, 34 (4), pp. 384–389.
- [3] Alvarez, J. V., Greulich, H., Sellers, W. R., Meyerson, M. and Frank, D. A. (2006). Signal Transducer and Activator of Transcription 3 Is Required for the Oncogenic Effects of Non-Small-Cell Lung Cancer-Associated Mutations of the Epidermal Growth Factor Receptor. *Cancer Research*, [online] 66 (6), pp. 3162–3168. Available at: <https://cancerres.aacrjournals.org/content/66/6/3162> [Accessed 26 Feb. 2021].
- [4] Ara, T., Song, L., Shimada, H., Keshelava, N., Russell, H. V., Metelitsa, L. S., Groshen, S. G., Seeger, R. C. and DeClerck, Y. A. (2009). Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. *Cancer Research*, [online] 69 (1), pp. 329–337. Available at: <https://pubmed.ncbi.nlm.nih.gov/19118018/> [Accessed 26 Feb. 2021].
- [5] Arcaro, A. and Guerreiro, A. (2007). The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications. *Current Genomics*, 8 (5), pp. 271–306.
- [6] Barradas, M., Gonos, E. S., Zebedee, Z., Kolettas, E., Petropoulou, C., Delgado, M. D., León, J., Hara, E. and Serrano, M. (2002). Identification of a Candidate Tumor-Suppressor Gene Specifically Activated during Ras-Induced Senescence. *Experimental Cell Research*, [online] 273 (2), pp. 127–137. Available at: <https://www.sciencedirect.com/science/article/pii/S0014482701954345> [Accessed 26 Feb. 2021].
- [7] Barré, B., Avril, S. and Coqueret, O. (2003). Opposite regulation of myc and p21waf1 transcription by STAT3 proteins. *The Journal of Biological Chemistry*, [online] 278 (5), pp. 2990–2996. Available at: <https://pubmed.ncbi.nlm.nih.gov/12438313/>.
- [8] Blaskovich, M. A., Sun, J., Cantor, A., Turkson, J., Jove, R. and Sefti, S. M. (2003). Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. *Cancer Research*, [online] 63 (6), pp. 1270–1279. Available at: <https://pubmed.ncbi.nlm.nih.gov/12649187/> [Accessed 26 Feb. 2021].
- [9] Bollrath, J., Phesse, T. J., von Burstin, V. A., Putoczki, T., Bennecke, M., Bateman, T., Nebelsiek, T., Lundgren-May, T., Canli, Ö., Schwitalla, S., Matthews, V., Schmid, R. M., Kirchner, T., Arkan, M. C., Ernst, M. and Greten, F. R. (2009). gp130-Mediated Stat Activation in Enterocytes Regulates Cell Survival and Cell-Cycle Progression during Colitis-Associated Tumorigenesis. *Cancer Cell*, [online] 15 (2), pp. 91–102. Available at: [https://www.cell.com/cancer-cell/supplemental/S1535-6108\(09\)00003-8](https://www.cell.com/cancer-cell/supplemental/S1535-6108(09)00003-8).
- [10] Bowman, T., Garcia, R., Turkson, J. and Jove, R. (2000). STATs in oncogenesis. *Oncogene*, [online] 19 (21), pp. 2474–2488. Available at: <https://pubmed.ncbi.nlm.nih.gov/10851046/> [Accessed 26 Feb. 2021].
- [11] Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C. and Darnell, J. E. (1999). Stat3 as an Oncogene. *Cell*, [online] 98 (3), pp. 295–303. Available at: [https://www.cell.com/cell/fulltext/S0092-8674\(00\)81959-5?code=cell-site](https://www.cell.com/cell/fulltext/S0092-8674(00)81959-5?code=cell-site) [Accessed 30 Oct. 2019].
- [12] Cantley, L. C. (2002). The Phosphoinositide 3-Kinase Pathway. *Science*, 296 (5573), pp. 1655–1657.
- [13] Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., Dalton, W. S. and Jove, R. (1999). Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells. *Immunity*, 10 (1), pp. 105–115.
- [14] Center for Disease control and prevention (2019). *What Are the Risk Factors for Cervical Cancer?* [online] Center for Disease control and prevention. Available at: https://www.cdc.gov/cancer/cervical/basic_info/risk_factors.htm.
- [15] Chen, T. M., Pecoraro, G. and Defendi, V. (1993). Genetic analysis of in vitro progression of human papillomavirus-transfected human cervical cells. *Cancer Research*, [online] 53 (5), pp. 1167–1171. Available at: <https://pubmed.ncbi.nlm.nih.gov/8382557/> [Accessed 25 Feb. 2021].

- [16] Darnell Jr., J. E. (1997). STATs and Gene Regulation. *Science*, 277 (5332), pp. 1630–1635.
- [17] Decker, T. and Kovarik, P. (2000). Serine phosphorylation of STATs. *Oncogene*, [online] 19 (21), pp. 2628–2637. Available at: <https://www.nature.com/articles/1203481> [Accessed 24 Jan. 2021].
- [18] Egan, S. E. and Weinberg, R. A. (1993). The pathway to signal achievement. *Nature*, [online] 365 (6449), pp. 781–783. Available at: <https://www.nature.com/articles/365781a0> [Accessed 26 Feb. 2021].
- [19] Frank, D. A. (1999). STAT signaling in the pathogenesis and treatment of cancer. *Molecular Medicine (Cambridge, Mass.)*, [online] 5 (7), pp. 432–456. Available at: <https://pubmed.ncbi.nlm.nih.gov/10449805/> [Accessed 26 Feb. 2021].
- [20] Fukami, T., Fukuhara, H., Kuramochi, M., Maruyama, T., Isogai, K., Sakamoto, M., Takamoto, S. and Murakami, Y. (2003). Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines. *International Journal of Cancer*, 107 (1), pp. 53–59.
- [21] Fukuhara, H., Kuramochi, M., Fukami, T., Kasahara, K., Furuhashi, M., Nobukuni, T., Maruyama, T., Isogai, K., Sekiya, T., Shuin, T., Kitamura, T., Reeves, R.H. and Murakami, Y. (2002). Promoter Methylation of TSLC1 and Tumor Suppression by Its Gene Product in Human Prostate Cancer. *Japanese Journal of Cancer Research*, 93 (6), pp. 605–609.
- [22] Gao, S. P., Mark, K. G., Leslie, K., Pao, W., Motoi, N., Gerald, W. L., Travis, W. D., Bornmann, W., Veatch, D., Clarkson, B. and Bromberg, J. F. (2007). Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. *The Journal of Clinical Investigation*, [online] 117 (12), pp. 3846–3856. Available at: <https://pubmed.ncbi.nlm.nih.gov/18060032/> [Accessed 26 Feb. 2021].
- [23] Ghaderi, M., Nikitina, L., Peacock, C. S., Hjelmström, P., Hallmans, G., Wiklund, F., Lenner, P., Blackwell, J. M., Dillner, J. and Sanjeevi, C. B. (2000). Tumor Necrosis Factor α -11 and DR15-DQ6 (B*0602) Haplotype Increase the Risk for Cervical Intraepithelial Neoplasia in Human Papillomavirus 16 Seropositive Women in Northern Sweden. *Cancer Epidemiology and Prevention Biomarkers*, [online] 9 (10), pp. 1067–1070. Available at: <https://cebp.aacrjournals.org/content/9/10/1067> [Accessed 25 Feb. 2021].
- [24] Gomyo, H., Arai, Y., Tanigami, A., Murakami, Y., Hattori, M., Hosoda, F., Arai, K., Aikawa, Y., Tsuda, H., Hirohashi, S., Asakawa, S., Shimizu, N., Soeda, E., Sakaki, Y. and Ohki, M. (1999). A 2-Mb sequence-ready contig map and a novel immunoglobulin superfamily gene IGSF4 in the LOH region of chromosome 11 q 23.2. *Genomics*, [online] 62 (2), pp. 139–146. Available at: <https://pubmed.ncbi.nlm.nih.gov/10610705/> [Accessed 26 Feb. 2021].
- [25] Govan, V. A., Constant, D., Hoffman, M. and Williamson, A.-L. (2006). The allelic distribution of -308 Tumor Necrosis Factor- α gene polymorphism in South African women with cervical cancer and control women. *BMC Cancer*, 6 (1).
- [26] Greulich, H.; Chen, T. H.; Feng, W.; Janne, P. A.; Alvarez, J. V.; Zappaterra, M.; Bulmer, S. E.; Frank, D. A.; Hahn, W. C.; Sellers, W. R.; et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. *PLoS Med.* 2005, 2, e313.
- [27] Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yi Yu, G., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L. and Karin, M. (2009). IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer. *Cancer Cell*, [online] 15 (2), pp. 103–113. Available at: <https://www.sciencedirect.com/science/article/pii/S153561080900026#sec3>.
- [28] Harada, D., Takigawa, N. and Kiura, K. (2014). The Role of STAT3 in Non-Small Cell Lung Cancer. *Cancers*, 6 (2), pp. 708–722.
- [29] Haura, E. B., Zheng, Z., Song, L., Cantor, A. and Bepler, G. (2005). Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research*, [online] 11 (23), pp. 8288–8294. Available at: <https://pubmed.ncbi.nlm.nih.gov/16322287/> [Accessed 26 Feb. 2021].
- [30] Honda, T., Tamura, G., Waki, T., Jin, Z., Sato, K., Motoyama, T., Kawata, S., Kimura, W., Nishizuka, S. and Murakami, Y. (2002). Hypermethylation of the TSLC1 Gene Promoter in Primary Gastric Cancers and Gastric Cancer Cell Lines. *Japanese Journal of Cancer Research*, 93 (8), pp. 857–860.
- [31] Hui, A. B.-Y., Lo, K.-W., Kwong, J., Lam, E. C.-W., Chan, S. Y.-Y., Chow, L. S.-N., Chan, A. S.-C., Teo, P. M.-L. and Huang, D. P. (2003). Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma. *Molecular Carcinogenesis*, 38 (4), pp. 170–178.
- [32] Hung, W. and Elliott, B. (2001). Co-operative Effect of c-Src Tyrosine Kinase and Stat3 in Activation of Hepatocyte Growth Factor Expression in Mammary Carcinoma Cells. *Journal of Biological Chemistry*, [online] 276 (15), pp. 12395–12403. Available at: [https://www.jbc.org/article/S0021-9258\(19\)46129-2/fulltext](https://www.jbc.org/article/S0021-9258(19)46129-2/fulltext) [Accessed 26 Feb. 2021].
- [33] Ito, T., Shimada, Y., Hashimoto, Y., Kaganoi, J., Kan, T., Watanabe, G., Murakami, Y. and Imamura, M. (2003). Involvement of TSLC1 in Progression of Esophageal Squamous Cell Carcinoma. *Cancer Research*, [online] 63 (19), pp. 6320–6326. Available at: <https://cancerres.aacrjournals.org/content/63/19/6320.short> [Accessed 26 Feb. 2021].
- [34] Jiang, R., Jin, Z., Liu, Z., Sun, L., Wang, L. and Li, K. (2011). Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma. *Molecular Diagnosis & Therapy*, [online] 15 (6), pp. 347–352. Available at: <https://pubmed.ncbi.nlm.nih.gov/22208386/> [Accessed 26 Feb. 2021].
- [35] Ke, S., Pandya-Jones, A., Saito, Y., Fak, J. J., Vågbø, C. B., Geula, S., Hanna, J. H., Black, D. L., Darnell, J. E. and Darnell, R. B. (2017). m6A mRNA modifications are deposited in nascent pre-mRNA and are not required for splicing but do specify cytoplasmic turnover. *Genes & Development*, 31 (10), pp. 990–1006.
- [36] Kok, K., Naylor, S. L. and Buys, C. H. C. M. (1997). Deletions of the Short Arm of Chromosome 3 in Solid Tumors and the Search for Suppressor Genes. [online] Science Direct. Available at: <https://www.sciencedirect.com/science/article/pii/S0065230X08600962> [Accessed 26 Feb. 2021].

- [37] Kortylewski, M., Xin, H., Kujawski, M., Lee, H., Liu, Y., Harris, T., Drake, C., Pardoll, D. and Yu, H. (2009). Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment. *Cancer Cell*, 15 (2), pp. 114–123.
- [38] Kujawski, M., Kortylewski, M., Lee, H., Herrmann, A., Kay, H. and Yu, H. (2008). Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. *Journal of Clinical Investigation*, 118 (10), pp. 3367–3377.
- [39] Kuramochi, M., Fukuhara, H., Nobukuni, T., Kanbe, T., Maruyama, T., Ghosh, H. P., Pletcher, M., Isomura, M., Onizuka, M., Kitamura, T., Sekiya, T., Reeves, R. H. and Murakami, Y. (2001). TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. *Nature Genetics*, [online] 27 (4), pp. 427–430. Available at: https://www.nature.com/articles/ng0401_427 [Accessed 25 Feb. 2021].
- [40] Lazo, P. A. (1999). The molecular genetics of cervical carcinoma. *British Journal of Cancer*, 80 (12), pp. 2008–2018.
- [41] Lesina, M., Kurkowski, Magdalena U., Ludes, K., Rose-John, S., Treiber, M., Klöppel, G., Yoshimura, A., Reindl, W., Sipos, B., Akira, S., Schmid, Roland M. and Algül, H. (2011). Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer. *Cancer Cell*, 19 (4), pp. 456–469.
- [42] Levy, D. E. and Darnell, J. E. (2002). STATs: transcriptional control and biological impact. *Nature Reviews Molecular Cell Biology*, 3 (9), pp. 651–662.
- [43] Li, Y., Du, H., Qin, Y., Roberts, J., Cummings, O. W. and Yan, C. (2007). Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. *Cancer Research*, [online] 67 (18), pp. 8494–8503. Available at: <https://pubmed.ncbi.nlm.nih.gov/17875688/> [Accessed 26 Feb. 2021].
- [44] Looyenga, B. D., Hutchings, D., Cherni, I., Kingsley, C., Weiss, G. J. and MacKeigan, J. P. (2012). STAT3 Is Activated by JAK2 Independent of Key Oncogenic Driver Mutations in Non-Small Cell Lung Carcinoma. *PLoS ONE*, 7 (2), p. e30820.
- [45] Lou, W., Ni, Z., Dyer, K., Tweardy, D. J. and Gao, A. C. (2000). Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway. *The Prostate*, 42 (3), pp. 239–242.
- [46] Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., Louis, D. N., Christiani, D. C., Settleman, J. and Haber, D. A. (2004). Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib. *New England Journal of Medicine*, 350 (21), pp. 2129–2139.
- [47] Mantovani, A., Allavena, P., Sica, A. and Balkwill, F. (2008). Cancer-related inflammation. *Nature*, 454 (7203), pp. 436–444.
- [48] Mao, X., Seidlitz, E., Truant, R., Hitt, M. and Ghosh, H. P. (2004). Re-expression of TSLC1 in a non-small-cell lung cancer cell line induces apoptosis and inhibits tumor growth. *Oncogene*, [online] 23 (33), pp. 5632–5642. Available at: <https://www.nature.com/articles/1207756> [Accessed 26 Feb. 2021].
- [49] Masuda, M., Yageta, M., Fukuhara, H., Kuramochi, M., Maruyama, T., Nomoto, A. and Murakami, Y. (2002). The Tumor Suppressor Protein TSLC1 Is Involved in Cell-Cell Adhesion. *Journal of Biological Chemistry*, [online] 277 (34), pp. 31014–31019. Available at: <https://www.sciencedirect.com/science/article/pii/S0021925820701882> [Accessed 26 Feb. 2021].
- [50] Mitsudomi, T. and Yatabe, Y. (2007). Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. *Cancer Science*, 98 (12), pp. 1817–1824.
- [51] Mora, L. B., Buettner, R., Seigne, J., Diaz, J., Ahmad, N., Garcia, R., Bowman, T., Falcone, R., Fairclough, R., Cantor, A., Muro-Cacho, C., Livingston, S., Karras, J., Pow-Sang, J. and Jove, R. (2002). Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. *Cancer Research*, [online] 62 (22), pp. 6659–6666. Available at: <https://pubmed.ncbi.nlm.nih.gov/12438264/> [Accessed 26 Feb. 2021].
- [52] M, S., H, R., K, M., JM, H., JA, M. and PM, H. (2013). *Human pathogenic papillomaviruses*. Springer.
- [53] Murakami, T., Takigawa, N., Ninomiya, T., Ochi, N., Yasugi, M., Honda, Y., Kubo, T., Ichihara, E., Hotta, K., Tanimoto, M. and Kiura, K. (2014). Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model. *Lung Cancer*, [online] 83 (1), pp. 30–36. Available at: [http://www.lungcancerjournal.info/article/S0169-5002\(13\)00455-8/pdf](http://www.lungcancerjournal.info/article/S0169-5002(13)00455-8/pdf) [Accessed 26 Feb. 2021].
- [54] Murakami, Y., Nobukuni, T., Tamura, K., Maruyama, T., Sekiya, T., Arai, Y., Gomyou, H., Tanigami, A., Ohki, M., Cabin, D., Frischmeyer, P., Hunt, P. and Reeves, R. H. (1998). Localization of tumor suppressor activity important in nonsmall cell lung carcinoma on chromosome 11q. *Proceedings of the National Academy of Sciences*, [online] 95 (14), pp. 8153–8158. Available at: <https://www.pnas.org/content/95/14/8153.short> [Accessed 26 Feb. 2021].
- [55] Niu, G., Bowman, T., Huang, M., Shivers, S., Reintgen, D., Daud, A., Chang, A., Kraker, A., Jove, R. and Yu, H. (2002). Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. *Oncogene*, [online] 21 (46), pp. 7001–7010. Available at: <https://pubmed.ncbi.nlm.nih.gov/12370822/> [Accessed 26 Feb. 2021].
- [56] O’Shea, J. J., Holland, S. M. and Staudt, L. M. (2013). JAKs and STATs in Immunity, Immunodeficiency, and Cancer. *New England Journal of Medicine*, 368 (2), pp. 161–170.
- [57] O’Shea, John J. and Plenge, R. (2012). JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease. *Immunity*, 36 (4), pp. 542–550.
- [58] Paez, J. G. (2004). EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. *Science*, 304 (5676), pp. 1497–1500.
- [59] Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., Mardis, E., Kupfer, D., Wilson, R., Kris, M. and Varmus, H. (2004). EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proceedings of the National Academy of Sciences*, 101 (36), pp. 13306–13311.

- [60] Parkin, D. M., Bray, F., Ferlay, J. and Pisani, P. (2005). Global Cancer Statistics, 2002. *CA: A Cancer Journal for Clinicians*, 55 (2), pp. 74–108.
- [61] Pishvaian, M. J., Feltes, C. M., Thompson, P., Bussemakers, M. J., Schalken, J. A. and Byers, S. W. (1999). Cadherin-11 Is Expressed in Invasive Breast Cancer Cell Lines. *Cancer Research*, [online] 59 (4), pp. 947–952. Available at: <https://cancerres.aacrjournals.org/content/59/4/947.short> [Accessed 26 Feb. 2021].
- [62] Shain, K. H., Yarde, D. N., Meads, M. B., Huang, M., Jove, R., Hazlehurst, L. A. and Dalton, W. S. (2009). Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. *Cancer Research*, [online] 69 (3), pp. 1009–1015. Available at: <https://pubmed.ncbi.nlm.nih.gov/19155309/> [Accessed 26 Feb. 2021].
- [63] Shen, Y., Devgan, G., Darnell, J. E. and Bromberg, J. F. (2001). Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. *Proceedings of the National Academy of Sciences of the United States of America*, [online] 98 (4), pp. 1543–1548. Available at: <https://pubmed.ncbi.nlm.nih.gov/11171987/> [Accessed 26 Feb. 2021].
- [64] Shingai, T., Ikeda, W., Kakunaga, S., Morimoto, K., Takekuni, K., Itoh, S., Satoh, K., Takeuchi, M., Imai, T., Monden, M. and Takai, Y. (2003). Implications of Nectin-like Molecule-2/IGSF4/RA175/SgIGSF/TSLC1/SynCAM1 in Cell-Cell Adhesion and Transmembrane Protein Localization in Epithelial Cells. *Journal of Biological Chemistry*, [online] 278 (37), pp. 35421–35427. Available at: [https://www.jbc.org/article/S0021-9258\(20\)83603-5/fulltext](https://www.jbc.org/article/S0021-9258(20)83603-5/fulltext) [Accessed 26 Feb. 2021].
- [65] Song, L., Turkson, J., Karras, J. G., Jove, R. and Haura, E. B. (2003). Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. *Oncogene*, [online] 22 (27), pp. 4150–4165. Available at: <https://pubmed.ncbi.nlm.nih.gov/12833138/> [Accessed 26 Feb. 2021].
- [66] Sordella, R. (2004). Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways. *Science*, 305 (5687), pp. 1163–1167.
- [67] Stanczuk, G. A., Sibanda, E. N., Tswana, S. A. and Bergstrom, S. (2003). Polymorphism at the -308-promoter position of the tumor necrosis factor-alpha (TNF-alpha) gene and cervical cancer. *International Journal of Gynecological Cancer*, 13 (2), pp. 148–153.
- [68] Steenbergen, R. D. M., Kramer, D., Braakhuis, B. J. M., Stern, P. L., Verheijen, R. H. M., Meijer, C. J. L. M. and Snijders, P. J. F. (2004). TSLC1 Gene Silencing in Cervical Cancer Cell Lines and Cervical Neoplasia. *JNCI: Journal of the National Cancer Institute*, [online] 96 (4), pp. 294–305. Available at: <https://academic.oup.com/jnci/article-abstract/96/4/294/2606709> [Accessed 26 Feb. 2021].
- [69] Sussan, T. E., Pletcher, M. T., Murakami, Y. and Reeves, R. H. (2005). Tumor suppressor in lung cancer 1 (TSLC1) alters tumorigenic growth properties and gene expression. *Molecular Cancer*, 4 (1), p. 28.
- [70] The American Cancer Society (2020). *What Is Cervical Cancer? | Types of Cervical Cancer*. [online] [www.cancer.org](https://www.cancer.org/cancer/cervical-cancer/about/what-is-cervical-cancer.html#:~:text=Adenocarcinomas%20are%20cancers%20that%20develop). Available at: <https://www.cancer.org/cancer/cervical-cancer/about/what-is-cervical-cancer.html#:~:text=Adenocarcinomas%20are%20cancers%20that%20develop> [Accessed 25 Feb. 2021].
- [71] Tsao, M.-S., Sakurada, A., Cutz, J.-C., Zhu, C.-Q., Kamel-Reid, S., Squire, J., Lorimer, I., Zhang, T., Liu, N., Daneshmand, M., Marrano, P., da Cunha Santos, G., Lagarde, A., Richardson, F., Seymour, L., Whitehead, M., Ding, K., Pater, J. and Shepherd, F. A. (2005). Erlotinib in lung cancer - molecular and clinical predictors of outcome. *The New England Journal of Medicine*, [online] 353 (2), pp. 133–144. Available at: <https://pubmed.ncbi.nlm.nih.gov/16014883/> [Accessed 26 Feb. 2021].
- [72] Urase, K., Soyama, A., Fujita, E. and Momoi, T. (2001). Expression of RA175 mRNA, a new member of the immunoglobulin superfamily, in developing mouse brain. *Neuroreport*, [online] 12 (15), pp. 3217–3221. Available at: <https://pubmed.ncbi.nlm.nih.gov/11711859/> [Accessed 26 Feb. 2021].
- [73] Verstovsek, S. (2009). Therapeutic potential of JAK2 inhibitors. *Hematology. American Society of Hematology. Education Program*, [online] pp. 636–642. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5166576/> [Accessed 29 Jul. 2020].
- [74] Vivanco, I. and Sawyers, C. L. (2002). The phosphatidylinositol 3-Kinase-AKT pathway in human cancer. *Nature Reviews Cancer*, 2 (7), pp. 489–501.
- [75] Wang, L., Yi, T., Kortylewski, M., Pardoll, D. M., Zeng, D. and Yu, H. (2009). IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. *The Journal of Experimental Medicine*, 206 (7), pp. 1457–1464.
- [76] Williams, K., Christensen, J. and Helin, K. (2011). DNA methylation: TET proteins—guardians of CpG islands? *EMBO reports*, 13 (1), pp. 28–35.
- [77] Xu, Y. H. and Lu, S. (2014). A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer. *European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology*, [online] 40 (3), pp. 311–317. Available at: <https://pubmed.ncbi.nlm.nih.gov/24332948/> [Accessed 26 Feb. 2021].
- [78] Yan, C., Naltner, A., Martin, M., Naltner, M., Fangman, J. M. and Gurel, O. (2002). Transcriptional Stimulation of the Surfactant Protein B Gene by STAT3 in Respiratory Epithelial Cells. *Journal of Biological Chemistry*, [online] 277 (13), pp. 10967–10972. Available at: [https://www.jbc.org/article/S0021-9258\(18\)52113-X/abstract](https://www.jbc.org/article/S0021-9258(18)52113-X/abstract) [Accessed 26 Feb. 2021].
- [79] Yang, Y., Kiss, H., Kost-Alimova, M., Kedra, D., Fransson, I., Seroussi, E., Li, J., Szeles, A., Kholodnyuk, I., Imreh, M. P., Fodor, K., Hadlaczky, G., Klein, G., Dumanski, J. P. and Imreh, S. (1999). A 1-Mb PAC Contig Spanning the Common Eliminated Region 1 (CER1) in Microcell Hybrid-Derived SCID Tumors. *Genomics*, [online] 62 (2), pp. 147–155. Available at: <https://www.sciencedirect.com/science/article/pii/S0888754399959529> [Accessed 26 Feb. 2021].

- [80] Yuan, B.-F. (2014). *Chapter Four - 5-Methylcytosine and Its Derivatives*. [online] ScienceDirect. Available at: <https://www.sciencedirect.com/science/article/pii/S0065242314000043>.
- [81] Yu, H. and Jove, R. (2004). The STATs of cancer — new molecular targets come of age. *Nature Reviews Cancer*, 4 (2), pp. 97–105.
- [82] Zhao, M., Gao, F.-H., Wang, J.-Y., Liu, F., Yuan, H.-H., Zhang, W.-Y. and Jiang, B. (2011). JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer. *Lung Cancer*, 73 (3), pp. 366–374.
- [83] Zhong, Z., Wen, Z. and Darnell, J. (1994). Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. *Science*, 264 (5155), pp. 95–98.
- [84] Zimmer, S., Kahl, P., Buhl, T. M., Steiner, S., Wardelmann, E., Merkelbach-Bruse, S., Buettner, R. and Heukamp, L. C. (2008). Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling. *Journal of Cancer Research and Clinical Oncology*, 135 (5), pp. 723–730.